GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » Common Stock

TME Pharma NV (XPAR:ALTME) Common Stock : €0.17 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is TME Pharma NV Common Stock?

TME Pharma NV's quarterly common stock declined from Dec. 2022 (€1.74 Mil) to Jun. 2023 (€0.05 Mil) but then increased from Jun. 2023 (€0.05 Mil) to Dec. 2023 (€0.17 Mil).

TME Pharma NV's annual common stock increased from Dec. 2021 (€0.75 Mil) to Dec. 2022 (€1.74 Mil) but then declined from Dec. 2022 (€1.74 Mil) to Dec. 2023 (€0.17 Mil).


TME Pharma NV Common Stock Historical Data

The historical data trend for TME Pharma NV's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV Common Stock Chart

TME Pharma NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.47 0.75 1.74 0.17

TME Pharma NV Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 1.36 1.74 0.05 0.17

TME Pharma NV Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


TME Pharma NV (XPAR:ALTME) Business Description

Traded in Other Exchanges
Address
Max-Dohrn-Street 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product candidates are; NOX-A12 and NOX-E36 are based on a new class of drug first developed by TME Pharma called Spiegelmers, which offer specific advantages over other drug classes.

TME Pharma NV (XPAR:ALTME) Headlines

No Headlines